๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for Platinum-resistant Ovarian Cancer

Vismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer NCT05538091Phase 21 site๐Ÿ“ Pittsburgh Ronald Buckanovich ยท Tests: Vismodegib, Atezolizumab Clinical Trial of Autologous B7-H3 CAR T Cells in Reoccurent Platinum-resistant Ovarian Tumors NCT06646627Phase 11 site๐Ÿ“ Palo Alto Stanford University ยท Tests: B7-H3CART GB-5267 for the Treatment Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer NCT07489287Phase 11 site๐Ÿ“ Buffalo Roswell Park Cancer Institute ยท Tests: GB-5267 - IV only, GB-5267 -Combined IV and IP Infusion Fuzuloparib Arsenic Trioxide Platinum Resistance Relapsed Ovarian Cancer NCT04518501Phase 1, Phase 21 site๐Ÿ“ Zhejiang Xing Xie ยท Tests: Arsenic trioxide Tablet +Fuzuloparib Capsules Adebrelimab Combined With Fuzuloparib in the Treatment of Patients With Recurrent Platinum-resistant Ovarian Cancer. NCT05753826Phase 21 site๐Ÿ“ Fujian Fujian Cancer Hospital ยท Tests: Adebrelimab, Fuzuloparib MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer NCT06483048Phase 11 site๐Ÿ“ Scottsdale Mayo Clinic ยท Tests: Autologous MUC1-activated T-cells, Bendamustine, Biospecimen Collection, Computed Tomography, Cyclophosphamide Exploratory Study on the Safety and Efficacy of Disitamab Vedotin in Combination with Anlotinib Hydrochloride for the Treatment of HER-2-expressing Recurrent Platinum-resistant Ovarian Cancer. NCT06660511EARLY Phase 11 site๐Ÿ“ Changsha Second Xiangya Hospital of Central South University ยท Tests: Disitamab Vedotin in Combination With Anlotinib Hydrochloride AZD5335 vs. Mirvetuximab Soravtansine in FRฮฑ-high and AZD5335 vs. Chemotherapy in FRฮฑ-low Platinum-resistant Ovarian Cancer NCT07218809Phase 3299 sites๐Ÿ“ Birmingham๐Ÿ“ Little Rock๐Ÿ“ La Jolla AstraZeneca ยท Tests: AZD5335, Mirvetuximab Soravtansine (MIRV), Paclitaxel, Pegylated liposomal Doxorubicin (PLD), Topotecan Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) NCT05579366Phase 1, Phase 266 sites๐Ÿ“ Phoenix๐Ÿ“ Tucson๐Ÿ“ Los Angeles Genmab ยท Tests: Rina-S, Carboplatin, Bevacizumab, Pembrolizumab, Erythromycin Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer NCT06787612Phase 256 sites๐Ÿ“ Birmingham๐Ÿ“ La Jolla๐Ÿ“ Los Angeles Regeneron Pharmaceuticals ยท Tests: Ubamatamab, Bevacizumab, Cemiplimab, Fianlimab, PLD A Study of SHR-A1811 in Subjects With Ovarian Cancer NCT06828354Phase 32 sites๐Ÿ“ Wuhan๐Ÿ“ Jinan Jiangsu HengRui Medicine Co., Ltd. ยท Tests: SHR-A1811, Paclitaxel Injection, Doxorubicin Hydrochloride Liposome Injection, Gemcitabine Hydrochloride for Injection,โ€ฆ Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells NCT06305299Phase 11 site๐Ÿ“ Chapel Hill UNC Lineberger Comprehensive Cancer Center ยท Tests: iC9-CAR.B7-H3 T cells, Cyclophosphamide, Fludarabine A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer NCT06710288Phase 22 sites๐Ÿ“ El Segundo๐Ÿ“ Newport Beach ImmunityBio, Inc. ยท Tests: Gemcitabine, N-803, M-CENK A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer NCT06161025Phase 2, Phase 3167 sites๐Ÿ“ Anchorage๐Ÿ“ New Haven๐Ÿ“ Coral Gables Daiichi Sankyo ยท Tests: R-DXd, Paclitaxel, Topotecan, PLD Efficacy and Safety of CapsuleX Combined With Cisplatin in Platinum-Resistant Recurrent Ovarian Cancer: A Single-Arm Prospective Clinical Study NCT07495384NA1 site๐Ÿ“ Changchun The First Hospital of Jilin University ยท Tests: CapsuleX A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer NCT07213804Phase 3265 sites๐Ÿ“ Birmingham๐Ÿ“ Phoenix๐Ÿ“ Burbank Eli Lilly and Company ยท Tests: Sofetabart Mipitecan, Paclitaxel, Topotecan, Gemcitabine, Pegylated liposomal doxorubicin (PLD) SMP-3124LP in Adults With Advanced Solid Tumors NCT06526819Phase 1, Phase 213 sites๐Ÿ“ Los Angeles๐Ÿ“ San Francisco๐Ÿ“ Denver Sumitomo Pharma America, Inc. ยท Tests: SMP3124LP A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression NCT07546500Phase 359 sites๐Ÿ“ Phoenix๐Ÿ“ Antioch๐Ÿ“ Beverly Hills K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis โ€ฆ ยท Tests: Investigator's choice of Chemotherapy, Azenosertib Survival Analysis in patiEnts With Bad Prognosis Epithelial Ovarian CArcinoma NCT07540403n/a1 site๐Ÿ“ Rome Fondazione Policlinico Universitario Agostino Gemelli IRCCS Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer NCT06856499Phase 12 sites๐Ÿ“ Aurora๐Ÿ“ Aurora University of Colorado, Denver ยท Tests: Cirtuvivint, Olaparib First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer NCT06799065Phase 1, Phase 211 sites๐Ÿ“ Aurora๐Ÿ“ Sarasota๐Ÿ“ Detroit Accent Therapeutics ยท Tests: ATX-295, ATX-295 and bevacizumab (or biosimilar) Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer NCT05998135Phase 21 site๐Ÿ“ Atlanta Emory University ยท Tests: Atovaquone, Biopsy, Computed Tomography, Paracentesis A Study of MGC026 in Participants With Advanced Solid Tumors NCT06242470Phase 112 sites๐Ÿ“ Los Angeles๐Ÿ“ Grand Rapids๐Ÿ“ Lake Success MacroGenics ยท Tests: MGC026 Dose Escalation, MGC026 Dose for Expansion, Pembrollizumab, vobramitamab tavatecan A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors NCT06515613Phase 115 sites๐Ÿ“ Little Rock๐Ÿ“ Beverly Hills๐Ÿ“ Denver Context Therapeutics Inc. ยท Tests: CTIM-76 Platino-resistance in Ovarian Cancer NCT03954171NA1 site๐Ÿ“ Toulouse Institut Claudius Regaud ยท Tests: Patients treated with platinum based-chemotherapy A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine NCT06682988Phase 252 sites๐Ÿ“ Sarasota๐Ÿ“ Edgewood๐Ÿ“ Lexington AbbVie ยท Tests: Mirvetuximab Soravtansine Telmisartan in Combination With Cytotoxic Regimens in Platinum-Resistant Ovarian Cancer NCT06815497Phase 22 sites๐Ÿ“ Lebanon๐Ÿ“ Manchester Tyler J Curiel ยท Tests: Telmisartan A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression NCT07023627Phase 274 sites๐Ÿ“ Mobile๐Ÿ“ Los Angeles๐Ÿ“ San Diego Incyte Corporation ยท Tests: INCB123667 A Study of SYS6043 in Platinum-Resistant, Advanced Ovarian, Primary Peritoneal, or Fallopian Tube Cancers NCT07708753Phase 31 site๐Ÿ“ Beijing CSPC Megalith Biopharmaceutical Co.,Ltd. ยท Tests: SYS6043, Liposomal doxorubicin, paclitaxel, or topotecan SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer NCT06394492Phase 32 sites๐Ÿ“ Beijing๐Ÿ“ Hangzhou Suzhou Suncadia Biopharmaceuticals Co., Ltd. ยท Tests: SHR-A1921, Doxorubicin, Paclitaxel, Topotecan
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy